Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Doroshow, James H"'
Autor:
Harris LN; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Blanke CD; SWOG Cancer Research Network, OHSU Knight Cancer Center, Portland, Oregon., Erba HP; Department of Medicine, Duke Cancer Center, Durham, North Carolina., Ford JM; Division of Oncology, Stanford University School of Medicine, Stanford, California., Gray RJ; Department of Data Science, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, Massachusetts., LeBlanc ML; SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington., Hu-Lieskovan S; Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah., Litzow MR; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Luger SM; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., O'Dwyer PJ; ECOG-ACRIN Cancer Research Group, University of Pennsylvania, Philadelphia, Pennsylvania., Othus MKD; Biostatistics, Public Health Division, Fred Hutchinson Cancer Center, Seattle, Washington., Politi K; Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut., Shepherd LE; Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada., Allegra CJ; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Chen HX; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Ivy SP; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Korde LA; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Little RF; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., McShane LM; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Moscow JA; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Patton DR; Clinical and Translational Research Branch, Center for Biomedical Informatics and Information Technology, NCI, Rockville, Maryland., Thurin M; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Yee LM; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Dec 01; Vol. 29 (23), pp. 4728-4732.
Autor:
Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ford JM; Department of Medicine - Oncology, Stanford University, Stanford, California., O'Dwyer PJ; Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., McShane LM; Biometric Research Program, DCTD, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Freidlin B; Biometric Research Program, DCTD, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., O'Cearbhaill RE; Department of Medicine, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, New York., George S; Sarcoma and Bone Oncology Division, Medical Oncology Department, Dana-Farber Cancer Institute, Boston, Massachusetts., Glade-Bender J; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., Lyman GH; Clinical Research Division, Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington., Tricoli JV; Diagnostic Biomarkers and Technology Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland., Patton D; Center for Biomedical Informatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Hamilton SR; Department of Pathology, City of Hope National Medical Center, Duarte, California., Gray RJ; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Hawkins DS; Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington., Ramineni B; Cancer Therapy Evaluation Program, Regulatory Affairs Branch, DCTD, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Flaherty KT; Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Grivas P; Department of Medicine, Division of Medical Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington., Yap TA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Berlin J; Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Moscow JA; Investigational Drug Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Apr 14; Vol. 29 (8), pp. 1412-1422.
Autor:
Nguyen J; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Takebe N; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Kummar S; Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon., Razak A; Princess Margaret Cancer Center, Toronto, Canada., Chawla SP; Sarcoma Oncology Center, Santa Monica, California., George S; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Patel SR; MD Anderson Cancer Center, Houston, Texas., Keohan ML; Memorial Sloan Kettering Cancer Center, New York, New York., Movva S; Fox Chase Cancer Center, Philadelphia, Pennsylvania., O'Sullivan Coyne G; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Do K; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Juwara L; Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Augustine B; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Steinberg SM; Center for Cancer Research, NCI, Bethesda, Maryland., Kuhlmann L; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Ivy SP; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.; Center for Cancer Research, NCI, Bethesda, Maryland., Chen AP; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Apr 03; Vol. 29 (7), pp. 1200-1208.
Autor:
O'Sullivan Coyne G; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Kummar S; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Hu J; University of Southern California, Los Angeles, California., Ganjoo K; Stanford Cancer Center, Stanford University, Palo Alto, California., Chow WA; City of Hope Medical Center, Duarte, California., Do KT; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Zlott J; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Bruns A; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Rubinstein L; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Foster JC; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Juwara L; Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Meehan R; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Piekarz R; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Streicher H; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Sharon E; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Takebe N; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Voth AR; Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Bottaro D; Center for Cancer Research, NCI, NIH, Bethesda, Maryland., Costello R; Center for Cancer Research, NCI, NIH, Bethesda, Maryland., Wright JJ; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Doroshow JH; Center for Cancer Research, NCI, NIH, Bethesda, Maryland.; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Chen AP; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland. chenali@mail.nih.gov.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Jan 15; Vol. 28 (2), pp. 279-288. Date of Electronic Publication: 2021 Oct 29.
Autor:
Chen HX; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), Bethesda, Maryland. thurinm@mail.nih.gov helen.chen@nih.gov., Song M; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), Bethesda, Maryland., Maecker HT; The Human Immune Monitoring Center (HIMC), Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, California., Gnjatic S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Patton D; Center for Biomedical Informatics and Information Technology, NCI, Bethesda, Maryland., Lee JJ; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Adam SJ; Foundation for the National Institutes of Health, North Bethesda, Maryland., Moravec R; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.; Kelly Services, Rockville, Maryland., Liu XS; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Cerami E; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Lindsay J; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Tang M; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Hodi FS; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Al-Atrash G; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bernatchez C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bendall SC; Department of Pathology, School of Medicine, Stanford University, Stanford, California., Hewitt SM; Laboratory of Pathology, Center for Cancer Research, NCI, Bethesda, Maryland., Sharon E; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), Bethesda, Maryland., Streicher H; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), Bethesda, Maryland., Enos RA; The Emmes Company, LLC, Rockville, Maryland., Bowman MD; The Emmes Company, LLC, Rockville, Maryland., Tatard-Leitman VM; The Emmes Company, LLC, Rockville, Maryland., Sanchez-Espiridion B; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ranasinghe S; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Pichavant M; The Human Immune Monitoring Center (HIMC), Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, California., Del Valle DM; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Yu J; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Janssens S; The Emmes Company, LLC, Rockville, Maryland., Peterson-Klaus J; Foundation for the National Institutes of Health, North Bethesda, Maryland., Rowe C; Center for Biomedical Informatics and Information Technology, NCI, Bethesda, Maryland.; Essex Management, Rockville, Maryland., Bongers G; Microbiome Translational Center, Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Jenq RR; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Chang CC; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Abrams JS; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), Bethesda, Maryland., Mooney M; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), Bethesda, Maryland., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Thurin M; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland. thurinm@mail.nih.gov helen.chen@nih.gov.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Sep 15; Vol. 27 (18), pp. 5038-5048. Date of Electronic Publication: 2021 Jan 08.
Autor:
Takebe N; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.; Center for Cancer Research, NCI, Bethesda, Maryland., Naqash AR; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., O'Sullivan Coyne G; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.; Center for Cancer Research, NCI, Bethesda, Maryland., Kummar S; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.; Center for Cancer Research, NCI, Bethesda, Maryland., Do K; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.; Center for Cancer Research, NCI, Bethesda, Maryland., Bruns A; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Juwara L; Clinical Monitoring Research Program, Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Zlott J; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Rubinstein L; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Piekarz R; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Sharon E; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Streicher H; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Mittra A; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Miller SB; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Ji J; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Wilsker D; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Kinders RJ; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Parchment RE; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Chen L; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Chang TC; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Das B; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Mugundu G; AstraZeneca, Clinical Pharmacology, Waltham, Massachusetts., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.; Center for Cancer Research, NCI, Bethesda, Maryland., Chen AP; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland. chenali@mail.nih.gov.; Center for Cancer Research, NCI, Bethesda, Maryland.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jul 15; Vol. 27 (14), pp. 3834-3844. Date of Electronic Publication: 2021 Apr 16.
Autor:
Massett HA; National Cancer Institute, Bethesda, Maryland. massetth@mail.nih.gov., Mishkin G; National Cancer Institute, Bethesda, Maryland., Moscow JA; National Cancer Institute, Bethesda, Maryland., Gravell A; The Emmes Company, Rockville, Maryland., Steketee M; Westat, Rockville, Maryland., Kruhm M; National Cancer Institute, Bethesda, Maryland., Han SH; National Cancer Institute, Bethesda, Maryland., Barry B; User-Centered Design Inc., Ashburn, Virginia., Montello M; National Cancer Institute, Bethesda, Maryland., Zwiebel J; National Cancer Institute, Bethesda, Maryland., Abrams JS; National Cancer Institute, Bethesda, Maryland., Doroshow JH; National Cancer Institute, Bethesda, Maryland., Ivy SP; National Cancer Institute, Bethesda, Maryland.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Dec 01; Vol. 25 (23), pp. 6925-6931. Date of Electronic Publication: 2019 Aug 22.
Autor:
Wilsker DF; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland. kindersr@mail.nih.gov deborah.wilsker@nih.gov., Barrett AM; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland., Dull AB; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland., Lawrence SM; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland., Hollingshead MG; Biological Testing Branch, NCI, Frederick, Maryland., Chen A; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Kummar S; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Parchment RE; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.; Developmental Therapeutics Branch, Center for Cancer Research, NCI, Bethesda, Maryland., Kinders RJ; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland. kindersr@mail.nih.gov deborah.wilsker@nih.gov.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 May 15; Vol. 25 (10), pp. 3084-3095. Date of Electronic Publication: 2019 Feb 21.
Autor:
Burton JH; School of Veterinary Medicine, University of California Davis, Davis, California., Mazcko C; Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., LeBlanc A; Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., Covey JM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Ji J; Clinical Pharmacodynamic Biomarker Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick, Maryland., Kinders RJ; Clinical Pharmacodynamic Biomarker Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick, Maryland., Parchment RE; Clinical Pharmacodynamic Biomarker Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick, Maryland., Khanna C; Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., Paoloni M; Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., Lana S; College of Veterinary Medicine, The Ohio State University, Columbus, Ohio., Weishaar K; College of Veterinary Medicine, The Ohio State University, Columbus, Ohio., London C; School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Kisseberth W; School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Krick E; School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin., Vail D; College of Veterinary Medicine, Purdue University, West Lafayette, Indiana., Childress M; College of Veterinary Medicine, University of Missouri-Columbia, Columbia, Missouri., Bryan JN; School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts., Barber L; College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois., Ehrhart EJ; College of Veterinary Medicine, The Ohio State University, Columbus, Ohio., Kent M; School of Veterinary Medicine, University of California Davis, Davis, California., Fan T; College of Veterinary Medicine, University of Florida, Gainesville, Florida., Kow K; College of Veterinary Medicine, University of Georgia, Athens, Georgia., Northup N; College of Veterinary Medicine, Texas A&M University, College Station, Texas., Wilson-Robles H; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania., Tomaszewski J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Holleran JL; Life Science Group, IIT Research Institute, Chicago, Illinois., Muzzio M; Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda., Eiseman J; Life Science Group, IIT Research Institute, Chicago, Illinois., Beumer JH; Life Science Group, IIT Research Institute, Chicago, Illinois., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda., Pommier Y; Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda. pommier@nih.gov.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2018 Dec 01; Vol. 24 (23), pp. 5830-5840. Date of Electronic Publication: 2018 Jul 30.
Autor:
Davidson NE, Armstrong SA, Coussens LM, Cruz-Correa MR, DeBerardinis RJ, Doroshow JH, Foti M, Hwu P, Kensler TW, Morrow M, Mulligan CG, Pao W, Platz EA, Smith TJ, Willman CL
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 Oct 01; Vol. 22 Suppl 19, pp. S1-S137.